Arthritis, Psoriatic

7
Pipeline Programs
5
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
5100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

MoonLake Immunotherapeutics
4 programs
1
3
SonelokimabPhase 3Monoclonal Antibody1 trial
SonelokimabPhase 3Monoclonal Antibody1 trial
SonelokimabPhase 3Monoclonal Antibody1 trial
SonelokimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05640245Completed207Est. Jan 2024
NCT06641089Recruiting600Est. Jan 2027
NCT06641076Active Not Recruiting960Est. Feb 2027
+1 more trials
UP
UCB PharmaBelgium - Brussels
1 program
1
CZP 200 mg Q2WPhase 31 trial
Active Trials
NCT01087788Completed409Est. Aug 2015
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
2
BI 730357Phase 21 trial
risankizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04680676Withdrawn0Est. Sep 2023
NCT02719171Completed185Est. Aug 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
MoonLake ImmunotherapeuticsSonelokimab
MoonLake ImmunotherapeuticsSonelokimab
MoonLake ImmunotherapeuticsSonelokimab
UCB PharmaCZP 200 mg Q2W
MoonLake ImmunotherapeuticsSonelokimab
Boehringer IngelheimBI 730357
Boehringer Ingelheimrisankizumab

Clinical Trials (7)

Total enrollment: 3,921 patients across 7 trials

NCT07223138MoonLake ImmunotherapeuticsSonelokimab

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Start: Nov 2025Est. completion: Feb 20281,560 patients
Phase 3Enrolling By Invitation
NCT06641076MoonLake ImmunotherapeuticsSonelokimab

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Start: Oct 2024Est. completion: Feb 2027960 patients
Phase 3Active Not Recruiting
NCT06641089MoonLake ImmunotherapeuticsSonelokimab

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Start: Oct 2024Est. completion: Jan 2027600 patients
Phase 3Recruiting
NCT01087788UCB PharmaCZP 200 mg Q2W

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Start: Mar 2010Est. completion: Aug 2015409 patients
Phase 3Completed
NCT05640245MoonLake ImmunotherapeuticsSonelokimab

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Start: Dec 2022Est. completion: Jan 2024207 patients
Phase 2Completed
NCT04680676Boehringer IngelheimBI 730357

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Start: May 2022Est. completion: Sep 20230
Phase 2Withdrawn
NCT02719171Boehringer Ingelheimrisankizumab

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Start: Apr 2016Est. completion: Aug 2017185 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 3,921 patients
Monoclonal Antibody is the dominant modality (100% of programs)
5 companies competing in this space